Higher and Standard Doses of Enteral Zinc Supplementation in Very Preterm Infants
Launched by PRINCE OF SONGKLA UNIVERSITY · Jan 12, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how two different doses of zinc supplements affect very preterm infants, who are babies born before 32 weeks of pregnancy and weigh less than 1800 grams. The researchers want to find out if a higher dose of zinc (10 mg per day) helps these babies grow better compared to a standard dose (1 mg per day). They will measure the babies' growth and development up to 24 months of age to see which dose is more beneficial.
To participate in this study, infants must be very preterm, born between 24 to 32 weeks of pregnancy, and weigh less than 800 grams when enrolled. They should also be stable and able to receive full feeding. However, infants with certain health issues, like infections or severe birth complications, will not be eligible. Parents of participating infants can expect to be closely monitored during the study, which will last at least two weeks. This research could provide important information on how to support the health and development of very preterm babies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Very preterm neonates (gestational age \[GA\]: 24 0/7-32 6/7 weeks and BW: 401-1800 grams) were consecutively admitted in the NICU and NMCU
- • Body weight at enrollment less than 800 grams
- • Stable neonates and full enteral feeding (150 mL/kg/day) at least for a few days
- Exclusion Criteria:
- • Outborn neonate who was admitted in study center after 7 days of life
- • Congenital infections
- • Malformations, syndromes, or genetic defects
- • Evidence of culture proven sepsis or necrotizing enterocolitis or death diagnosed before enrollment
- • Gastrointestinal (GI) surgery or high GI fluid output (usually ileostomy losses)
- • Unstable neonate during weighing including on intercostal drainage tube or drainage
- • Neonates need diuretics more than 7 days
- • Severe birth asphyxia (5-minute Apgar score less than 4)
- • Parents' decision not to participate the study
About Prince Of Songkla University
Prince of Songkla University (PSU) is a prestigious academic institution located in Thailand, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, PSU leverages its extensive resources and expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among multidisciplinary teams of researchers, healthcare professionals, and students, ensuring rigorous study designs and adherence to ethical standards. PSU's dedication to improving public health outcomes is reflected in its focus on translating research findings into practical applications that benefit local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hat Yai, Songkhla, Thailand
Patients applied
Trial Officials
Anucha Thatrimontrichai, MD
Principal Investigator
Prince of Songkla University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported